Business
Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.
About this update from Lakefront Biotherapeutics
[{"type":"text","content":"$52M equity adds to previously announced $165M Series A","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group","length":366,"tagName":"p","attribs":{}},{"type":"text","content":"SPRING HOUSE, Pa., Feb. 4, 2026 /PRNewswire/ -- Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.","length":290,"tagName":"p"},{"type":"image","alt":"Third Arc Bio logo (PRNewsfoto/Third Arc Bio)","displaySize":"","headline":null,"caption":"Third Arc Bio logo (PRNewsfoto/Third Arc Bio)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":63,"url":"https://media.zenfs.com/en/prnewswire.com/2d63d4a07a10754e281887e62ce1f0c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CUc8xvSs9MzW4tT.3yampQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2d63d4a07a10754e281887e62ce1f0c8","width":400,"height":63}},"href":"https://mma.prnewswire.com/media/2465382/Third_Arc_Bio_Full_Color_RGB_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"New investor Andreessen Horowitz (a16z) joined Third Arc Bio's existing world-class investor syndicate to further validate the company's approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio's Board of Directors. Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the clinic.","length":460,"tagName":"p"},{"type":"text","content":""Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease," said Jorge Conde, General Partner at a16z. "The company&...